Across TCGA pan-cancer cohorts, TEKT4P2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TEKT4P2 data layer compared with 16 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TEKT4P2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEKT4P2 expression acts as an unfavorable survival marker.
SKCM are the cancer types where TEKT4P2 Mutation most reproducibly stratifies survival.